Key facts
- This page summarizes Keane Raymond T.'s Form 4 filing for Cullinan Oncology, Inc. (CGEM).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 15 Feb 2022, 15:48.
Keane Raymond T. - 11 Feb 2022 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)
- Reporting relationship
- Chief Legal Officer
- Issuer ticker
- CGEM
- Reported as of
- 11 Feb 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/ Jeffrey Trigilio, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Keane Raymond T. filed Form 4 for Cullinan Oncology, Inc. (CGEM) on 15 Feb 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CGEM
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +22,500
- Change %
- +1385%
- Price
- $0.000000
- Shares after
- 24,124
- Date
- 11 Feb 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CGEM
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +45,000
- Change %
- Price
- $0.000000
- Shares after
- 45,000
- Date
- 11 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 45,000
- Exercise price
- $13.60
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares underlying the restricted stock unit vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
Footnote F2
The shares underlying the option vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.